SBC Medical Group Holdings, Inc.

# Financial Highlights

November 2024

### Disclaimer



This presentation contains certain financial measures that are not recognized under generally accepted accounting principles in the United States ("GAAP"), including EBITDA and EBITDA margin. For a reconciliation of these non-GAAP financial measures to the most directly comparable GAAP measures, see GAAP to Non-GAAP Measures Reconciliation. This presentation contains forward-looking statements. These statements are made under the "safe harbor" provisions of the U.S. Private Securities Litigation Reform Act of 1995. These forwardlooking statements can be identified by terminology such as "may," "will," "expect," "anticipate," "future," "aim," "estimate," "intend," "seek," "plan," "believe," "potential," "continue," "ongoing," "target," "guidance," "is/are likely to" and similar statements. In addition, statements that are not historical facts, including statements about SBC Medical's strategies and business and operational plans, management's beliefs, outlook, expectations and guidance regarding the growth of its business, revenue and return on investments, capital policy in this presentation, are or contain forward-looking statements. SBC Medical may also make forward-looking statements in its periodic reports to the U.S. Securities and Exchange Commission (the "SEC"), in announcements made on its website, in press releases and other written materials and in oral statements made by its officers, directors or employees to third parties. Forward-looking statements involve inherent risks and uncertainties. A number of factors could cause actual results to differ materially from those contained in any forward-looking statement. Further information regarding these and other risks is included in SBC Medical's filings with the SEC. All information provided in this presentation is as of the date of this presentation and are based on assumptions that we believe to be reasonable as of this date, and SBC Medical does not undertake any obligation to update any forward-looking statement, except as required under applicable law.

### 3Q24 YTD Highlights: Growth Across the Board



Almost all key figures have experienced growth relative to 3Q23 YTD.

### SBC Medical Group Holdings Key Financials (24Q3 YTD)

#### **Total revenues**

\$160м

**(YoY +23%)** 

#### EBITDA\*1

\$68м

**(YoY +21%)** 

### **EBITDA Margin\***<sup>2</sup>

**42**%

(YoY (1)pt)

#### **Net Income**

attributable to SBC Medical Group Holdings Incorporated

\$40м

(YoY + 60%)

**ROE** (annualized) \*3

31%

(YoY + 1pt)

#### EPS (basic) \*4

\$0.42

(YoY + 56%)

### **Franchise Clinics Key Figures**

#### **Number of Franchise clinics**

Sep24

224 clinics

(vs Sep23 +24 clinics)

#### **Number of customers**

(Excl. free counseling)

Oct23 - Sep24

4.3м

(YoY +13.5%)

<sup>\*1</sup> EBITDA = Income from operations + Depreciation and amortization expense \*2 EBITDA Margin (%) = EBITDA / Total revenues


<sup>\*3</sup> ROE = Net income attributable to SBC Medical Group Holdings Incorporated (annualized) / Average of SBC Medical Group Holdings Incorporated's stockholder's equity (beginning of the period and end of the period)

<sup>\*4</sup> EPS (basic) = Net income attributable to SBC Medical Group Holdings Incorporated / Weighted average shares outstanding

### Revenue Growth Driven by Diverse Services



- Revenue has steadily increased in line with the expansion of number of clinics.
- Management services decreased mainly by the stop of staffing services.




\*Exchange Rate(Year-To-Date Ave.) 23Q3 138.102 JPY/USD 24Q3 151.127 JPY/USD

### EBITDA\*1 Growth Driven by Top Line



- EBITDA has also been steadily increased.
- "Stock-based compensation expenses" is one time expense related to the listing process.
   (mm US\$)



### Robust Balance Sheet Positioned for Growth




SBC's balance sheet is strong with ample cash and borrowing capacity.

### Key Balance Sheet Figures (as of September 30, 2024)









### **Selected items from Balance Sheet**

(mm US\$)	Dec 31, 2023	June 30, 2024	Sep 30, 2024	QoQ
Total assets	258	255	296	+41
Total current assets	165	169	202	+32
Cash and cash equivalent	103	103	137	+33
Property and equipment, net	13	11	13	+1
Intangible assets, net	19	14	16	+1
Long-term investments in MCs –related parties	19	17	19	+2
Total liabilities	114	94	90	(3)
Current liabilities	92	75	72	(2)
Total Stockholder's equity	143	160	205	+44
SBC Medical Group Holdings Incorporated's stockholders' equity	142	160	204	+44

<sup>\*1</sup> D/E Ratio = Total Debt / Total Stockholders' equity

<sup>\*2</sup> Current Ratio = Total current assets / Total current liabilities

<sup>\*3</sup> Capital Ratio = SBC Medical Group Holdings Incorporated's stockholder's equity / Total assets

### Public Shareholder Driven Capital Policy



• Shareholder return, growth investment, and building a strong capital base are all important considerations to ensure value creation reflecting our commitment to public shareholders.

**Shareholder Return** 

Maximizing SBC's shareholder value with robust business growth

**Growth Investment** 

 SBC prioritizes continuous investment in both organic and inorganic growth opportunities to expand our franchise network

**Building Capital Base** 

• To support SBC's sustainable growth, building a strong capital base is another vital factor in our capital policy



## Appendix

### Income Statement (Consolidated)



#### **Income Statement**

	FY23	23Q3	24Q3		23Q3	24Q3	
(mm US\$)	YTD	YTD	YTD	% YoY			% YoY
Total revenues	193	131	160	+23%	47	53	+12%
Royalty income	42	25	45	+79%	8	15	+82%
Procurement services	53	34	44	+28%	8	17	+96%
Management services	72	53	44	(17)%	22	12	(47)%
Rental services	7	4	11	+139%	1	4	+208%
Other	18	12	15	+23%	5	3	(34)%
Cost of Revenues	56	37	38	+4%	13	9	(29)%
Gross Profit	137	93	122	+30%	33	43	+29%
Operating expenses	66	47	56	+20%	13	29	+118%
Income from operations	70	46	65	+41%	20	13	(31)%
Net income attributable to SBC Medical Group Holdings Incorporated	39	25	40	+60%	8	2	(66)%

### **Operating Expenses**

(m	nm US\$)	23Q3 YTD	24Q3 YTD	% YoY
To	otal operating expenses	47	56	+20%
	Salaries and welfare	20	21	+6%
	Depreciation and amortization expense	8	1	(78)%
	Consulting and professional service fees	5	10	+74%
	Office, utility and other expenses	5	5	+(7)%
	Other	7	18	+153%





(mm US\$)	Dec 31, 2023	June 30, 2024	Sep 30, 2024	QoQ
Total assets	258	255	296	+41
Total current assets	165	169	202	+32
Cash and cash equivalent	103	103	137	+33
Account receivable – related parties	33	23	27	+3
Customer loans receivable	8	14	16	+1
Other assets	20	27	20	(6)
Total non-current assets	92	85	94	+8
Property and equipment, net	13	11	13	+1
Intangible assets, net	19	14	16	+1
Customer loans receivable	6	6	6	(0)
Long-term investments in MCs  – related parties	19	17	19	+2
Other assets	33	34	38	+4

	Dec 31,	June 30,	Sep 30,		
(mm US\$)	2023	2024	2024	QoQ	
Total liabilities	114	94	90	(3)	
Total current liabilities	92	75	72	(2)	
Accounts payable	26	14	14	+0	
Notes payable –related parties	3	9	10	+0	
Advances from customers – related parties	23	15	18	+3	
Income tax payable	8	12	8	(4)	
Other current liabilities	30	22	20	(1)	
Total non-current liabilities	22	19	18	(1)	
Notes payable – related parties	11	14	11	(2)	
Other non-current liabilities	10	5	6	+1	
Stockholder's equity	143	160	205	+44	
SBC Medical Group Holdings Incorporated's stockholders' equity	142	160	204	+44	





(mm US\$)	FY23 YTD	23Q3 YTD	24Q3 YTD	% YoY
Net cash provided by operating activities	50	22	27	+23%
Net cash provided by (used in) investing activities	1	8	(5)	(164)%
Net cash provided by financing activities	6	6	11	+85%
Effect of changes in foreign currency exchange rate	(7)	(11)	0	-
Net change in cash and cash equivalents	51	25	34	+85%
Cash and cash equivalents as of the beginning of the period	51	51	103	+99%
Cash and cash equivalents as of the end of the period	103	77	137	+77%





	(mm US\$)	23Q3 YTD	24Q3 YTD	23Q3	24Q3
(A)	Total Revenues	131	160	47	53
(B)	Income from operations	46	65	20	13
(C)	Depreciation and amortization expense	9	2	3	1
(D) = (B) + (C)	EBITDA	56	68	23	14
$(E) = (D) \angle (A)$	EBITDA Margin	43%	42%	49%	28%